Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2021-02-04 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于发行境外上市外资股（H股）申请材料获中国证监会受理的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (602 characters) regarding the acceptance by the China Securities Regulatory Commission (CSRC) of the company's application materials for issuing overseas listed foreign shares (H shares) and listing on the Hong Kong Stock Exchange. It states that the application has been accepted and is under review, with further approvals pending. There is no detailed financial data, no full report, and the document is primarily an official regulatory announcement about the status of a capital market application. It is not a full capital/financing update report but an announcement of the acceptance of application materials. Given the short length and nature of the content, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document rather than a full Capital/Financing Update (CAP) or other report type.
2021-02-04 Chinese
2020年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2020 annual performance forecast (业绩预告) from 贝达药业股份有限公司, covering the period from January 1, 2020 to December 31, 2020. It provides estimated net profit figures and explanations for performance changes but explicitly states that the forecast has not been audited and that detailed financial data will be disclosed in the 2020 annual report. The document is short (969 characters) and serves as an earnings preview rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. Therefore, the correct classification is ER with high confidence. FY 2020
2021-01-28 Chinese
2021年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2021 first extraordinary general meeting (临时股东大会) of 贝达药业股份有限公司. It includes voting results on multiple proposals, attendance details, and legal opinions confirming the validity of the meeting and resolutions. The content is focused on shareholder meeting decisions and voting outcomes rather than financial results, management changes, or other report types. The document is not a full annual or interim report, nor is it a presentation or earnings release. It is a formal declaration of voting results from a shareholders' meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is over 10,000 characters and contains substantive voting data, so it is not a mere announcement of a report publication (RPA). Therefore, the correct classification is DVA with high confidence.
2021-01-22 Chinese
股东减持股份预披露的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement by a shareholder (温州特瑞西创企业管理合伙企业) of 贝达药业股份有限公司 regarding their planned reduction of shareholding. It details the number of shares held, the planned reduction amount, methods of reduction (centralized bidding and block trades), timing, and reasons for the reduction. The document includes legal compliance statements and risk warnings related to the share reduction. There is no financial data, earnings information, or report content. This is a notification of a shareholder's planned shareholding change, which fits the definition of a Major Shareholding Notification (MRQ). The document length is short (1653 characters), and it is not an announcement of a report publication or a certification. Therefore, the correct classification is MRQ with high confidence.
2021-01-22 Chinese
2021年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance qualifications, agenda, and voting results of a company's 2021 first extraordinary general meeting (临时股东大会). It details the legal compliance of the meeting process and the validity of the resolutions passed. The document includes extensive voting results on various proposals, including share issuance and board member elections. This type of document is typically associated with the official declaration of voting results from a shareholder meeting. It is not a full annual or interim report, nor a management discussion or earnings release. It is not a proxy solicitation or a report publication announcement. The document is lengthy and detailed, not a brief announcement. Therefore, the best fitting category is "Declaration of Voting Results & Voting Rights Announcements (DVA)".
2021-01-22 Chinese
关于2021年第一次临时股东大会的提示性公告
AGM Information Classification · 100% confidence The document is a detailed announcement regarding the convening of the 2021 first extraordinary general meeting (临时股东大会) of Betta Pharmaceuticals Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), agenda items for shareholder approval, registration details, and proxy forms. The content focuses on informing shareholders about the meeting logistics and the proposals to be voted on, including issuance of H shares and board member elections. There are no financial statements or management discussion and analysis present. The document is not a report itself but an announcement and notice related to a shareholders' meeting. Therefore, it fits the category of AGM Information (AGM-R).
2021-01-21 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.